ReviewMedical oncology (Northwood, London, England)2011
Diversity of axin in signaling pathways and its relation to colorectal cancer.
Review in Medical oncology (Northwood, London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- The Association between ABO Blood Group and the Risk of Colorectal Cancer: A Systematic Literature Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2023Pooled it
- Zbed3 promotes proliferation and invasion of lung cancer partly through regulating the function of Axin-Gsk3β complex.Journal of cellular and molecular medicine · 2019Article
- Alternative splicing within the Wnt signaling pathway: role in cancer development.Cellular oncology (Dordrecht, Netherlands) · 2016Review
- Tankyrases: structure, function and therapeutic implications in cancer.Current pharmaceutical design · 2014Review
- SignaLink 2 - a signaling pathway resource with multi-layered regulatory networks.BMC systems biology · 2013Article
- Wnt/beta-catenin signaling and small molecule inhibitors.Current pharmaceutical design · 2013Review
- The destruction complex of beta-catenin in colorectal carcinoma and colonic adenoma.Einstein (Sao Paulo, Brazil)Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer is one of the commonest cancers in western world, while majority of cases of CRC are sporadic, a significant minority occurs as a result of inherited genetic mutations. Various studies have demonstrated that tumorigenesis of colon arises as a result of accumulation of multiple genetic alterations targeting the single signal transduction pathway. Genetic alteration of axin has been implicated in different cancers including colorectal cancers. Axin being a multidomain protein interacts with multiple proteins and acts as major scaffold protein in signaling pathways like c-jun/SAPK, TGF-β, and Wnt. In different signaling pathways, axin utilizes different domains and hence exerts distinct roles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.